Health Herz Act: New measures for comprehensive prevention and better health care

Health Herz Act: New measures for comprehensive prevention and better health care

"Health Heart Law (GHG): A key to better health care and care"

Berlin (July 17, 2024) - The health sector in Germany always endeavors to improve health care and prevention measures. In this context, Pharma Germany has welcomed the new Health Herz Herz Act (GHG) and sees it a significant step towards preventing cardiovascular diseases, strokes, metabolic syndrome and kidney diseases. These diseases often occur together and require extensive prevention measures at all levels.

The GHG aims to ensure that diagnostic options, education and therapies are more easily accessible. Dorothee Brakmann, general manager of Pharma Germany, emphasizes the importance of cooperation of all health professions and the use of digital options. It suggests that the GHG should use digital health treatments (DIGA) for information, education and accompanying those affected as well as for therapy.

Another important aspect that Pharma emphasizes Germany is the equivalence of all prevention measures. The GHG should ensure that both established and new measures, such as tobacco cessation, are assessed equally in the interests of the health system. The focus should be on prevention of diseases in order to protect resources in the long term and relieve the health system. The GHG should therefore be designed accordingly.

Pharma Deutschland e.V. is the pharmaceutical association in Germany with the highest membership and is committed to the interests of the German pharmaceutical industry. The association promotes the dialogue between politics, business and society to ensure sustainable and innovative health care. He represents the interests of the industry with around 400 member companies.

Your contacts: Berlin office: Bonn office:
Hannes Hönemann
Head of Press and Public Relations Department
t. 030/308 75 96 - 138
hoenemann@pharmadeutschland.de
aileen Wagefeld-Dalitz
CVD press and public relations
t. 030/308 75 96-123
wagefeld@pharmadeutschland.de
Pharma Germany e.V.
Friedrichstraße 134
10117 Berlin
Pharma Germany e.V.
Ubierstraße 71-73
53173 Bonn
www.pharmadeutschland.de

Health care and care are of great importance for the population of Germany. The Health Heart Law (GHG) is an important instrument to strengthen the prevention of cardiovascular diseases and other serious diseases. It is necessary to bring all health professions together and use digital solutions to make diagnostic options, education and therapies more effective. It should also be ensured that all prevention measures, whether old or new, are rated equally to ensure just health care. Pharma Germany is committed to advanced and sustainable health care and supports the GHG as an important step in the right direction.

Kommentare (0)